Opko Health, Inc. - Common Stock (OPK)

Sale of BioReference brings $722 million in cash as the company narrows its focus to biotech.

OPKO Health (NASDAQ:OPK) reported 16% growth in third-quarter revenue from continuing operations and outlined plans to focus on drug development and pharmaceutical products following its proposed sale of BioReference assets to Labcorp. The transaction, announced Oct. 15, would provide approximately

OPKO Health (NASDAQ:OPK) outlined a strategy to shift its business mix toward therapeutics while continuing to streamline its diagnostics operations, with management highlighting a pipeline of early-stage clinical programs, external collaborations and capital available to fund development. Speaking

It posted a beat-and-raise second quarter.

Gainers OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.

OPKO Health (NASDAQ:OPK) reported a narrower second-quarter loss as gains tied to its diagnostics restructuring and a China commercialization agreement helped lift revenue, while the company continued to increase investment in clinical development programs. Total revenue for the second quarter of 2

OPKO Health (OPK) Q4 2025 Earnings Call Transcript

OPKO Health Q3 2025 earnings beat estimates with a surprise profit, driving a positive market reaction despite a revenue miss.

OPKO Health's Q2 2025 earnings missed revenue and EPS estimates, causing a 7.8% stock drop. Weak performance in pharma/diagnostics segments and higher losses raised investor concerns.